U.S. Genomics, Inc. company has developed the GeneEngine, a DNA sequencer that mimics natural cell division, rapidly reading and copying DNA. It is developing the technology to quickly detect and identify infectious pathogens and biomarkers for biodefense and diagnostic use. Its products can detect and quantify molecules of DNA, RNA, and proteins without amplification. Backed by private equity investors and biomedical firms including Becton Dickinson, U.S. Genomics has netted contracts with the Department of Homeland Security. Northrup Gruman is the company's bio-security development partner.

Celgene Corporation company was founded in 1980 and is headquartered in Summit, New Jersey. Celgene Corporation engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases primarily in Europe and the United States. Its primary commercial stage products include REVLIMID for the treatment in combination with dexamethasone for multiple myeloma patients, as well as for the treatment of patients with transfusion-dependent anemia; and THALOMID for the treatment in combination with dexamethasone of patients with newly diagnosed multiple myeloma, as well as for the treatment and suppression of cutaneous manifestations of erythema nodosum leprosum.Celgene Corporation company also sells ALKERAN for the palliative treatment of multiple myeloma and of carcinoma of the ovary; VIDAZA, which is used for the treatment of various subtypes of MDS; RITALIN that is used for the treatment of attention deficit hyperactivity disorder; and FOCALIN for the treatment of oncology-related disorders. Its development stage products consist of CC-4047, which is in Phase II trials for the treatment of myelofibrosis and multiple myeloma, and in Phase I trials for the treatment of hemoglobinopathies; CC-10015 that is in pre-clinical stage for the treatment of inflammatory diseases; CC-10004, which is in Phase II clinical trials for the treatment of psoriasis, psoriatic arthritis, and inflammatory diseases; JNK CC-930 that is in Phase I trial to treat fibrotic diseases; Amrubicin, which is in Phase III trials for small cell lung cancer treatment; Human umbilical cord blood, a Phase I trials product to treat transplants and hematological disorders; and ACE-011, a Phase II initiated product for multiple myeloma/Bone loss treatment. Celgene Corporation has strategic collaborations with Acceleron Pharma, Inc. for the joint development and commercialization of ACE-011; and GlobeImmune Inc. to develop molecular immunotherapy for the treatment of cancer.

ConjuChem Biotechnologies Inc. (ConjuChem) is a Canadian biotechnology company dedicated to the discovery of therapeutics with an initial focus on diabetes. The Company is focused on discovering and developing new drugs based on its technology platforms called Drug Affinity Complex (DAC) and Preformed Conjugate-Drug Affinity Complex (PC-DAC). The Company has developed the DAC Technology, a platform that enables the rapid creation of improved, patentable drugs from existing small organic compounds or peptides. The Company also designs drugs to treat an array of pathologies, such as diabetes, cancer and human immunodeficiency virus (HIV). ConjuChem has multiple research programs in-house and has one product in clinical trials.

LEO Pharma- UK lays claim to being king of the dermatology drug jungle in the UK. LEO Pharma UK company, which is the British arm of Denmark's LEO Pharma, handles the sales and marketing LEO's dermatological and critical care pharmaceutical products in the UK. LEO Pharma UK also has a growing medical department which conducts clinical studies on behalf of the group. The parent company focuses on topical prescription medications for psoriasis and other dermatological conditions. The group's lead critical care products include anticoagulant heparin (derived from porcine mucosa) and vitamin D.

Allergy Research Group Inc. offers nutritional supplement products. It offers amino acids, antioxidant formulas, bioenergetics, bioflavonoids, blood sugar, books, brain, cardiovascular, comprehensive formulas, fatty acids, eye, gastric support, glandulars, and hormone products. Allergy Research Group also provides immune support, liver support, martin pall products, metabolic support, microbial balancers, minerals, multiples, musculoskeletal, probiotics, specialty products, vitamin B products, vitamin C products, and vitamin D, E, K products. The company was founded in 1979 and is headquartered in Alameda, California. As of September 9, 2008, Allergy Research Group Inc. operates as a subsidiary of KI NutriCare, Inc.

Brothers Charles and Theophil Gebauer founded the company in 1898. Gebauer's Salivart will make your mouth water. Seriously, that's what it's designed to do for people who suffer from xerostomia, better known as dry mouth. That's not all Gebauer makes, however. The company offers medications for topical use, including Ethyl Chloride for the treatment of pain; Instant Ice, for the relief of muscle spasms, strains, bruising, and other injuries; and Spray and Stretch, for myofacial pain and minor sports injuries. Gebauer also provides contract manufacturing as well as project planning, packaging and labeling, and distribution services for other drug makers.

Ceregene is developing gene therapies for a variety of central nervous system disorders. Its pipeline includes two leading candidates in clinical trials: CERE-120 is being investigated for treatment of Parkinson's disease while CERE-110 is being tested on Alzheimer's disease. Both candidates are based upon Ceregene's technology that delivers neurotrophic factors directly into dying neuron cells. The neurotrophic factors are then able to delay the progression of neurodegenerative diseases. Two other candidates are being developed to treat ALS and certain ocular diseases. Genzyme has joined into a partnership to develop and commercialize CERE-120. Additional funding has come from the Michael J. Fox Foundation.

Hycor Biomedical makes medical diagnostic products and sells them in the US and abroad. Hycor's KOVA urinalysis system, which enables labs to perform uniform microscopic analyses of urine specimens, is used in applications including personnel safety and pregnancy testing. Hycor company also produces allergy diagnosis products and kits for detecting rheumatoid arthritis and other autoimmune diseases. Its products are sold by distributors and the company's sales force. Hycor Biomedical is a subsidiary of life sciences company Agilent.

Contract Pharmacal Corp. (CPC) is a full-service contract research organization serving pharmaceutical companies, retailers, and wholesalers worldwide. CPC manufactures dietary supplements, a variety of over-the-counter medications, and private label and generic prescription drugs. The company's prescription portfolio consists of mostly of prenatal and multi-vitamins, as well as urinary tract infection treatments. Production capabilities also include manufacturing tablets, gelatin capsules, softgels, and liquids that can be packaged in bottles, cans, blister pouches, and cartons. CPC (in business since 1971) is owned and operated by CEO Matt Wolf and the founding Wolf family.

Nutra Pharma Corporation was founded in 2000 and is based in Boca Raton, Florida. Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.